Voyager Therapeutics (NASDAQ:VYGR) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen has downgraded Voyager Therapeutics (NASDAQ:VYGR) from a "hold" to a "sell" rating, despite a broader "Moderate Buy" consensus among analysts with an average price target of $13.75 compared to the current trading price of $3.49. Recent insider selling by CEO Alfred Sandrock contrasts with significant institutional buying, such as EcoR1 Capital increasing its stake to over 4 million shares. Voyager Therapeutics is a clinical-stage biotechnology company focusing on gene therapies for neurological diseases, utilizing proprietary platforms for AAV vector development.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of "Moderate Buy" by Brokerages
Voyager Therapeutics (NASDAQ:VYGR) has received an average "Moderate Buy" rating from brokerages, with five buy recommendations and one sell. Analysts have set a mean one-year price target of $13.75 for the stock, which is currently trading near its 52-week lows. Insider selling by CEO Alfred Sandrock and other company insiders has been noted, while institutional investors hold approximately 48.03% of the company's shares.
Voyager Therapeutics Announces Chief Medical Officer Resignation
Voyager Therapeutics (VYGR) announced that its Chief Medical Officer, Toby Ferguson, M.D., Ph.D., resigned effective February 20, 2026, to pursue a new opportunity. President and CEO Alfred W. Sandrock, Jr., M.D., Ph.D. will assume interim medical and strategic responsibilities for the clinical development portfolio. While the company stated the departure was amicable, the interim leadership structure's impact on development initiatives will be observed.
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced its participation in several upcoming investor conferences in February and March 2026. The biotechnology company, focused on neurological diseases, will engage in fireside chats at events hosted by Guggenheim, Oppenheimer, TD Cowen, Leerink, and Stifel, with a webcast available for the Oppenheimer conference. Voyager specializes in leveraging genetics to treat conditions like Alzheimer’s, Parkinson’s, and ALS, utilizing its TRACER™ AAV capsid discovery platform.
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics, Inc. announced its participation in several upcoming investor conferences in February and March 2026. The biotechnology company will hold fireside chats at events such as the Guggenheim Emerging Outlook: Biotech Summit, Oppenheimer 36th Annual Healthcare Life Sciences Conference, TD Cowen 46th Annual Health Care Conference, Leerink Global Healthcare Conference, and Stifel 2026 CNS Days. A webcast of the Oppenheimer fireside chat will be available on Voyager's website.
Biotech Voyager lines up five investor conference talks through March
Voyager Therapeutics (Nasdaq: VYGR) announced it will present at five investor conferences between February and March 2026. These include events hosted by Guggenheim, Oppenheimer, TD Cowen, Leerink, and Stifel. A webcast of the Oppenheimer fireside chat will be available on the company's investors website, with a replay archived for at least 30 days.
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics, Inc. announced its participation in multiple upcoming investor conferences in February and March 2026. The biotechnology company will present at the Guggenheim Emerging Outlook: Biotech Summit, Oppenheimer 36th Annual Healthcare Life Sciences Conference, TD Cowen 46th Annual Health Care Conference, Leerink Global Healthcare Conference, and Stifel 2026 CNS Days. These events will feature fireside chats where Voyager will discuss its progress in leveraging genetics to treat neurological diseases.
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM)
Three analysts recently provided bullish sentiments on healthcare companies Voyager Therapeutics (VYGR), InflaRx (IFRX), and Verastem (VSTM). H.C. Wainwright reiterated a Buy rating for Voyager Therapeutics with a $25.00 price target and for InflaRx with a $6.00 price target. Mizuho Securities also reiterated a Buy rating for Verastem, setting a price target of $15.00.
FY2030 Earnings Forecast for VYGR Issued By HC Wainwright
HC Wainwright has issued a FY2030 EPS forecast of ($0.83) for Voyager Therapeutics (NASDAQ:VYGR) and reiterated a "Buy" rating with a $25 price target. This forecast is slightly more optimistic than the consensus estimate of ($0.91) per share. Voyager Therapeutics, despite being unprofitable, recently surpassed previous EPS and revenue estimates, reporting ($0.47) EPS against ($0.53) consensus and $11.15 million in revenue against $7.86 million estimates.
Voyager Therapeutics (NASDAQ:VYGR) Stock Crosses Below Fifty Day Moving Average - What's Next?
Voyager Therapeutics (NASDAQ:VYGR) stock has fallen below its fifty-day moving average to $3.98, signaling a technical downturn. Despite remaining unprofitable, the company recently surpassed quarterly EPS and revenue estimates. Analysts currently rate VYGR as a "Moderate Buy" with a consensus price target of $13.75, indicating a potential rebound.
Gene Therapy Market Outlook 2026-2031, Featuring Profiles of REGENXBIO, Oxford Biomedica, Voyager Therapeutics and More
The global gene therapy market is projected to grow from USD 7.54 billion in 2025 to USD 13.02 billion by 2031, driven by supportive regulatory frameworks and increased investment in life sciences. Key challenges include the high complexity and cost of manufacturing, leading to expensive treatments. However, strategic partnerships with CDMOs and a shift towards in vivo administration are helping to overcome these hurdles and expand therapeutic options.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of "Moderate Buy" from Analysts
Voyager Therapeutics (NASDAQ:VYGR) has received a "Moderate Buy" consensus rating from analysts, with five buy recommendations and one sell. The average 12-month price target is $13.75, significantly higher than its current trading price of $3.67. Despite beating recent earnings estimates, the company remains unprofitable, and institutional investors hold about 48% of its shares.
Voyager Therapeutics, Inc. Highlights 2026 Milestones and Developments
Voyager Therapeutics, Inc. has outlined its key developments and expectations for 2026, focusing on advancements in tau-targeting therapies and NeuroShuttle technology. The company plans first-in-human dosing of VY1706 for Alzheimer's and expects data from the VY7523 anti-tau antibody trial in the second half of 2026. Additionally, a new trial for Friedreich's ataxia is set to begin in 2026, and the ALPL-NeuroShuttle program is generating partner interest due to its sustained brain exposure.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of "Moderate Buy" from Analysts
Voyager Therapeutics, Inc. (NASDAQ:VYGR) has an average "Moderate Buy" rating from six analysts, with a 12-month average price target of $12.15. The company recently reported better-than-expected Q3 EPS of -$0.47 and revenue of $11.15 million, but remains unprofitable with a negative net margin. Insider activity shows CFO Nathan D. Jorgensen sold 7,666 shares, reducing his stake, while institutional investors hold 48.03% of the stock.
Voyager Throws 30 Staff Overboard After Novartis Sinks Two Programs
Voyager Therapeutics is laying off 30 employees after Novartis discontinued two undisclosed discovery-stage programs in their gene therapy collaboration. Despite these setbacks, Voyager stated that its cash runway guidance would not be impacted, and programs for spinal muscular atrophy and Huntington’s disease with Novartis are advancing. Voyager is also progressing its lead asset VY7523 for Alzheimer's disease and other gene therapies for the same condition.
Alzheimer's, ALS, And Huntington's Programs Keep Voyager Therapeutics On Investor Radar
Voyager Therapeutics is advancing its pipeline targeting neurological diseases like Alzheimer's, ALS, and Huntington's, with key clinical milestones expected in 2025 and 2026. The company is actively collaborating with partners like Transition Bio and Neurocrine Biosciences, while also developing its NeuroShuttle delivery platform. Voyager projects its current cash reserves to fund operations into 2028, bolstered by potential milestone payments from its partnerships.
Voyager Therapeutics, Inc. $VYGR Shares Sold by Armistice Capital LLC
Armistice Capital LLC reduced its stake in Voyager Therapeutics (NASDAQ:VYGR) by 11.7%, selling 636,000 shares and retaining 4,800,000 shares, representing about 8.65% of the company. Despite this sale, analysts maintain a "Moderate Buy" consensus rating with an average price target of $12.15, while the stock trades near $4.41 amidst a negative net margin. The company reported better-than-expected quarterly EPS but still faces significant financial challenges.
Voyager Therapeutics (VYGR): Strong Q3 Prompts Bullish Coverage
Voyager Therapeutics Inc (NASDAQ:VYGR) reported strong Q3 results, beating analyst expectations for both loss per share and revenue. Despite a lowered price target from HC Wainwright, the firm maintained a Buy rating, citing Voyager's cash position and potential partner milestones. The company, focused on neurological disease cures, also provided updates on drug development at the Citi Biopharma conference.
Voyager Therapeutics (VYGR): Strong Q3 Prompts Bullish Coverage
Voyager Therapeutics (NASDAQ:VYGR) reported strong Q3 2025 results, with $229M in cash, an operational runway into 2028, and eligibility for up to $2.4B in partner milestones. Despite an analyst price target reduction to $25 from $30, the company maintained a Buy rating and surpassed analyst expectations for both loss per share and revenue. Voyager Therapeutics focuses on human genetics for neurological disease cures.
Voyager Therapeutics Reports Increased Losses Amid Rising R&D Costs
Voyager Therapeutics (VYGR) reported increased net losses in Q3 2025, reaching $27.9 million compared to $9 million in Q3 2024, primarily due to rising research and development costs and decreased collaboration revenue. Despite these challenges, the biotechnology company maintains a strong cash position of $229 million, which is expected to fund operations for at least the next year as it continues to advance its gene therapy pipeline for neurological diseases.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of "Moderate Buy" from Analysts
Six research firms have given Voyager Therapeutics, Inc. (NASDAQ:VYGR) an average rating of "Moderate Buy," with five "buy" ratings and one "sell" rating. The average one-year price target from analysts is approximately $12.15, significantly higher than its current share price near $3.95. Despite recent positive EPS results, the company remains unprofitable, and analysts project a negative EPS for the current fiscal year.
Benign Growth For Voyager Therapeutics, Inc. (NASDAQ:VYGR) Underpins Stock's 26% Plummet
Voyager Therapeutics, Inc. (NASDAQ:VYGR) has seen its shares drop 26% recently, contributing to a 30% decline over the past year. The company's price-to-sales (P/S) ratio of 7x is significantly lower than the industry average, which is attributed to declining revenue and a forecast of weaker growth compared to the biotechnology sector. Analysts predict 33% annual growth for Voyager Therapeutics over the next three years, while the industry is expected to grow by 115%.
Earnings Update: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Voyager Therapeutics, Inc. (NASDAQ:VYGR) reported third-quarter results with revenues exceeding estimates by 70%, leading to lower-than-expected statutory losses. Analysts have updated their forecasts, projecting a significant revenue increase for 2026 but also a pronounced increase in loss per share. Despite mixed views on valuation, the consensus price target remains steady at US$15.00, implying that increased forecast losses are not expected to have a long-term impact on the company’s valuation.
Earnings Update: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Voyager Therapeutics (NASDAQ:VYGR) recently released its third-quarter results, showing revenues of US$13m, exceeding estimates by 70%. Despite steady revenue forecasts, analysts have increased their loss per share forecasts for 2026, though the consensus price target remains at US$15.00, suggesting limited long-term impact on valuation. The company is expected to see significant revenue growth, outperforming competitors in its industry.
Voyager, Transition Bio set sail on neuro research trek in search of small molecule candidates
Voyager Therapeutics is partnering with Transition Bio to discover and develop small molecules targeting protein bundles linked to neurodegenerative diseases, such as ALS and frontotemporal dementia. Voyager will provide an upfront payment and potential milestone payments up to $500 million, while Transition Bio will use its platform to identify molecules that bind to TDP-43 and correct its mislocalization. This collaboration marks Voyager's first entry into the small molecule space, complementing its existing biologics and gene therapy efforts.
Voyager Therapeutics Inc earnings beat by $0.05, revenue topped estimates
Voyager Therapeutics Inc (NASDAQ: VYGR) reported Q3 EPS of $-0.470, beating analyst estimates by $0.05, and revenue of $13.37M, surpassing the consensus estimate of $7.86M. The stock price was up 14.520% in the last three months but down -39.230% in the last 12 months. According to InvestingPro, the company has a "fair performance" financial health score.
Voyager Reports Third Quarter 2025 Financial and Operating Results
Voyager Therapeutics announced its Q3 2025 financial and operating results, highlighting progress in its tau programs with clinical data for VY7523 expected and VY1706 entering clinical trials in 2026. The company also introduced the Voyager NeuroShuttle™ discovery program and entered a collaboration with Transition Bio for small molecules targeting TDP-43 in ALS and FTD. Voyager ended the quarter with $229 million in cash, projecting a runway into 2028.
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
Transition Bio and Voyager Therapeutics have entered a collaboration to discover and develop small molecules targeting TDP-43 pathology in ALS and frontotemporal dementia. Transition Bio will be responsible for discovery and optimization, with Voyager holding an option to license development and commercialization rights. The agreement includes an upfront payment to Transition Bio and potential milestone payments and royalties.
Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates
Voyager Therapeutics (VYGR) reported a Q3 loss of $0.47 per share, outperforming the Zacks Consensus Estimate of a $0.53 loss. The company's revenues for the quarter reached $13.37 million, exceeding estimates by 57.01%. Despite topping revenue estimates, VYGR's shares have underperformed the S&P 500 year-to-date, and the stock currently holds a Zacks Rank #3 (Hold).
Voyager Therapeutics, Inc. SEC 10-Q Report
Voyager Therapeutics, Inc. has released its Q3 2025 10-Q report, detailing a decrease in collaboration revenue but an increase in R&D expenses, leading to a higher net loss. The report highlights the company's progress in its gene therapy pipeline for neurological diseases, including clinical trials for VY7523 and anticipated IND application for VY1706, supported by strategic collaborations and a projection of cash resources into 2028.
Voyager Therapeutics Reports Third Quarter 2025 Financial and Operating Results
Voyager Therapeutics has released its Q3 2025 financial and operational results, reporting an increased net loss of $27.9 million due to decreased collaboration revenue and higher R&D expenses. The company is advancing its pipeline, including VY7523 for Alzheimer's and the new NeuroShuttle™ platform, while maintaining a strong cash position projected into 2028.
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) has received a "Moderate Buy" consensus rating from nine research firms, with an average 12-month price target of $13.25. The company reported a significant earnings miss in its last quarter, with an EPS loss of ($0.57) against an estimated ($0.48), and lower-than-expected revenue. Insider trading also occurred, with CFO Nathan D. Jorgensen selling shares.
BIO China Deal Perspectives: A Dramatic Impact On Industry’s R&D Pipelines
This article discusses the significant impact of China's drug development landscape on the global industry's R&D pipelines. It highlights how investors and drug developers outside of China are actively seeking to integrate Chinese assets into their development strategies. The rapid pace of Chinese drug development is noted as an attractive factor for these collaborations.
Voyager expects FA gene therapy to enter clinical testing in 2026
Voyager Therapeutics plans to begin clinical testing of its experimental gene therapy for Friedreich’s ataxia (FA) in 2026, after submitting an investigational new drug application to the FDA this year. The gene therapy aims to deliver a healthy copy of the FXN gene using a viral vector that can cross the blood-brain barrier, potentially addressing neurological complications. Voyager is also developing a gene therapy for disorders caused by GBA1 protein mutations, which is also expected to enter clinical trials next year.
7 Analysts Assess Voyager Therapeutics: What You Need To Know
Seven analysts have provided ratings for Voyager Therapeutics (NASDAQ: VYGR) over the last three months, resulting in an average 12-month price target of $21.1, a 13.28% decrease from the previous average. While analysts largely maintain bullish ratings, the company faces financial challenges including a 93.03% revenue decline as of December 2024 and negative returns on equity and assets. The article emphasizes the importance of combining analyst insights with other financial indicators for a comprehensive understanding.
Voyager Enters into License for Next-Generation Capsid,
Voyager Therapeutics announced a new license agreement with Novartis AG for a novel capsid generated from Voyager’s TRACER™ capsid discovery platform. This agreement involves an upfront payment of $15 million to Voyager, with potential earnings of up to $305 million in milestone payments and royalties. This expands their partnered gene therapy portfolio to 14 programs, strengthening their collaboration in neurogenetic medicines.
Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
Voyager Therapeutics (Nasdaq: VYGR) announced it will release its second quarter 2024 financial and operating results after market close on Tuesday, August 6, 2024. The company will subsequently host a conference call and webcast at 4:30 p.m. ET to discuss the results. Interested participants can register in advance for the call, or access a live webcast and replay on the Investors section of Voyager's website.
Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
Voyager Therapeutics has appointed Nathan Jorgensen, Ph.D., MBA, as its new Chief Financial Officer, effective July 8, 2024. Jorgensen brings extensive experience in investment banking, healthcare investing, and biotech operational roles, including his most recent position as CFO for Vor Biopharma Inc. This strategic hire aims to strengthen Voyager's financial position and advance its neurotherapeutics pipeline.
Voyager Therapeutics Announces Pricing of Public Offering
Voyager Therapeutics announced the pricing of an underwritten public offering of common stock and pre-funded warrants, aiming to raise approximately $100 million. The company plans to use the net proceeds to advance its neurogenetic medicine programs, including clinical development for Alzheimer's and ALS treatments. Citigroup, Guggenheim Securities, and Oppenheimer & Co. are managing the offering, which is expected to close around January 9, 2024.
Voyager Therapeutics enters Capsid license agreement with Novartis to advance novel gene therapies
Voyager Therapeutics has announced a strategic collaboration and capsid license agreement with Novartis Pharma AG to advance gene therapies for Huntington’s disease and spinal muscular atrophy. Under the terms, Novartis will pay Voyager $100 million upfront, including a $20 million equity purchase, and Voyager is eligible to receive up to $1.2 billion in milestones plus royalties. The agreement grants Novartis target-exclusive access to Voyager’s TRACER capsids for SMA and worldwide rights to Voyager’s AAV gene therapy for HD.
Novartis signs gene therapy deal with Voyager for $100 mln upfront
Voyager Therapeutics announced a licensing deal with Novartis worth $100 million upfront, allowing Novartis to develop gene therapy candidates for genetic disorders. Voyager could receive up to $1.2 billion in milestones and tiered royalties for providing Novartis access to its RNA-based screening platform. The collaboration includes developing a pre-clinical gene therapy for Huntington's disease and exploring treatments for spinal muscular atrophy.
Novartis deepens ties with Voyager via $100M gene therapy deal
Novartis announced a new collaboration with Voyager Therapeutics, licensing an experimental gene therapy for Huntington’s disease and gene therapy delivery tools for spinal muscular atrophy. The deal involves an upfront payment of $100 million and could be worth up to $1.3 billion, further strengthening Novartis's position in gene therapy and its existing ties with Voyager. This collaboration allows Novartis to pursue difficult neurological targets and leverage Voyager's TRACER technology.
Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson’s disease
This study investigates the long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of Parkinson's disease patients. Researchers found no evidence of cerebral parenchyma toxicity up to five years post-infusion, highlighting the safety and targeting value of real-time imaging with co-infused therapeutic agents. This delivery-imaging platform enhances safety, permits personalized delivery, and improves therapeutic distribution.
Al Sandrock takes on CEO role at gene therapy developer
Al Sandrock, former head of clinical development at Biogen, has been appointed CEO of gene therapy company Voyager Therapeutics. Sandrock's illustrious career at Biogen involved the discovery and development of blockbuster multiple sclerosis treatments, and he now brings his expertise to Voyager, which focuses on neurological diseases. His appointment follows recent strategic shifts at Voyager and major deals with Pfizer and Novartis to utilize its gene therapy technology.
Al Sandrock, former top scientist at Biogen, named CEO at Voyager Therapeutics
Al Sandrock, the former top scientist at Biogen, has been appointed CEO of Voyager Therapeutics after his departure from Biogen last year. His move to Voyager Therapeutics marks a new chapter focused on gene therapy delivery technology, following setbacks in his previous role related to the controversial Alzheimer's drug Aduhelm.
Novartis turns to Voyager for nervous system gene therapies
Novartis has entered into a deal with Voyager Therapeutics to license its capsid technology for gene therapies targeting nervous system disorders. The agreement involves an upfront payment of $54 million, licensing fees, and potential milestone payments up to $1.5 billion, giving Novartis access to Voyager's viral shells for specified central nervous system targets. This collaboration aims to overcome the challenges of delivering gene therapies across the blood-brain barrier, expanding Novartis's significant presence in gene therapy research.
Novartis pays $150M for access to UCB’s Parkinson’s drug
Novartis has paid UCB $150 million upfront for co-development rights to UCB0599, an experimental oral drug targeting alpha-synuclein in Parkinson's disease. The deal includes an option for a second Parkinson's treatment and could see UCB earn up to $1.5 billion in additional payments. The companies will share development costs, with UCB commercializing in Europe and Novartis globally.
Voyager Therapeutics’ stock jumps 57% following Pfizer licensing deal
Voyager Therapeutics' stock surged 57% after the company announced a licensing agreement with Pfizer. Under the deal, Voyager will license novel capsids from its TRACER screening technology to Pfizer for gene therapies. The agreement includes an upfront payment of $30 million, potential additional payments of $20 million, and up to $580 million in development, regulatory, and commercial milestones, plus royalties on net sales.
Voyager Therapeutics Announces License Option Agreement
Voyager Therapeutics announced a license option agreement with Pfizer for its TRACER™ AAV capsids, aimed at advancing neurologic and cardiovascular gene therapy programs. Voyager receives an upfront payment of $30 million, with potential for up to $600 million in milestone payments and royalties. This collaboration grants Pfizer access to Voyager's novel capsids, which have shown enhanced blood-brain-barrier penetration and cardiac muscle tropism.
Voyager Therapeutics CEO and CMO Resign as Company Undergoes Strategic Shift
Voyager Therapeutics' CEO Andre Turenne and CMO Omar Khwaja are departing the company following clinical setbacks with a Parkinson’s disease program. The company is undergoing a strategic shift to focus on its adeno-associated virus (AAV) TRACER technology, with Michael Higgins stepping in as interim CEO and Glenn Pierce as interim CSO. This shift aims to capitalize on new gene therapy candidates for neurological diseases, including its lead asset for Huntington's disease, VY-HTT01, which is set to begin Phase I/II trials.
